Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

DOI: 10.1186/s40880-018-0330-z

Keywords: Nasopharyngeal carcinoma, Famitinib, Concurrent chemoradiotherapy, Phase I, dynamic contrast-enhanced ultrasound

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1186/s40880-018-0330-z) contains supplementary material, which is available to authorized users

Full-Text